SCHEMBL3201285

SCHEMBL3201285

Cc1ccc(NC(=O)Nc2cccc(CN3CCN(/C(=N\C#N)N4CCN(C)CC4)CC3)c2F)cn1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.41
DHODH Q02127 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CCR3 P51677 3/20 0.38
MAPK8 P45983 2/20 0.38
MAPK10 P53779 2/20 0.38
ABL1 P00519 5/20 0.37
SRC P12931 3/20 0.37
FGFR4 P22455 4/20 0.37
NPSR1 Q6W5P4 1/20 0.37
EPHX2 P34913 1/20 0.36
DDX3X O00571 1/20 0.36
ABL2 P42684 2/20 0.36
MAPK14 Q16539 1/20 0.36
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3201292 1.00 RORC (0.41) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3215178 0.94 RORC (0.44) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3215173 0.94 RORC (0.44) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3210277 0.92 RORC (0.40) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3198122 0.89 NPC1 (0.49) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3211025 0.88 RORC (0.46) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3206801 0.88 CCR3 (0.39) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3206805 0.88 CCR3 (0.39) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL3196716 0.85 NPC1 (0.53) RORCDHODHNPC1RAB9ASMN1; SMN2
SCHEMBL4237706 0.85 RORC (0.48) RORCDHODHNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-8871768-B2 Certain chemical entities, compositions and methods CYTOKINETICS, INC. (US) 2014-10-28 US disclosed
US-20130324549-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2013-12-05 US disclosed
US-8445495-B2 Certain Chemical entities, compositions and methods CYTOKINETICS, INC. (US) 2013-05-21 US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 RORC 2972/4885DHODH 3762/4885NPC1 4691/4885
US-20130324549-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS TNNI3, TNNT2, MYLK2 RORC 2972/4885DHODH 3762/4885NPC1 4691/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 RORC 2972/4885DHODH 3762/4885NPC1 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.